Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ENPEP | Q07075 | 6/20 | 0.46 |
| ▸ | ANPEP | P15144 | 3/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | BMP1 | P13497 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | GABRE | P78334 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27999571 | 1.00 | ALOX15 (0.54) | ALOX15BLMPMP22KMT2AENPEP | |
| SCHEMBL4283479 | 1.00 | ALOX15 (0.54) | ALOX15BLMPMP22KMT2AENPEP | |
| SCHEMBL284914 | 0.88 | ENPEP (0.52) | ALOX15BLMPMP22KMT2AENPEP | |
| SCHEMBL289006 | 0.88 | ENPEP (0.52) | ALOX15BLMPMP22KMT2AENPEP | |
| SCHEMBL289102 | 0.85 | ENPEP (0.62) | BLMKMT2AENPEPANPEPLTA4H | |
| SCHEMBL288129 | 0.85 | ENPEP (0.62) | BLMKMT2AENPEPANPEPLTA4H | |
| SCHEMBL42056 | 0.85 | ENPEP (0.62) | BLMKMT2AENPEPANPEPLTA4H | |
| SCHEMBL3690946 | 0.83 | ENPEP (0.60) | BLMKMT2AENPEPANPEPLTA4H | |
| Hydrochloric Acid SCHEMBL7366627 | 0.83 | ENPEP (0.60) | BLMKMT2AENPEPANPEPLTA4H | |
| SCHEMBL16860717 | 0.83 | ENPEP (0.64) | ALOX15BLMPMP22KMT2AENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | claimed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| WO-2025224179-A1 | GLUTAMINYL CYCLASE INHBITORS FOR USE IN THE TREATMENT OF KIDNEY DISEASE | VIVORYON THERAPEUTICS N.V. (DE) | 2025-10-30 | — | — | WO | disclosed |
| WO-2024241086-A1 | PEGYLATED BOVINE INTERFERON LAMBDA AND METHODS OF USE THEREOF | AMBRX, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024178310-A1 | TROP2-DIRECTED ANTIBODY-DRUG CONJUGATES AND USES THEREOF | AMBRX, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-11793855-B2 | TFPI inhibitors and methods of use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| WO-2010127704-A1 | BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100173847-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173847-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2010071894-A2 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | ALOX15 1296/4885BLM 1402/4885PMP22 353/4885 |
| US-20100173847-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, SERPINC1 | ALOX15 1863/4885BLM 4538/4885PMP22 558/4885 |
| US-11793855-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F3 | ALOX15 2429/4885BLM 4503/4885PMP22 756/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | ALOX15 355/4885BLM 3021/4885PMP22 4263/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | ALOX15 4319/4885BLM 2382/4885PMP22 2272/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | ALOX15 355/4885BLM 3021/4885PMP22 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.